NCT01483963CompletedPhase 2
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Endo Pharmaceuticals30 sites in 1 country50 target enrollmentStarted: November 1, 2011Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 50
- Locations
- 30
- Primary Endpoint
- Change From Baseline to Day 92 in Active Forward Flexion
Study Overview
Brief Summary
The objectives of this study are to assess the safety, effectiveness, and immunogenicity of AA4500 in the treatment of adhesive capsulitis.
Detailed Description
This study is a Phase 2a, open-label, dose-ranging study of the safety and effectiveness of AA4500 for the treatment of adhesive capsulitis of the shoulder. To be eligible for treatment, a subject must have unilateral idiopathic adhesive capsulitis of the shoulder with restricted range of motion in the affected shoulder for at least 3 months but not more than 12 months. Subjects will be screened for study eligibility within 30 days before injection of study drug.
Approximately 50 adult women and men are to be enrolled in this study. Following screening and determination of study eligibility, Assignment to Cohorts 1-4 is sequential. Subjects assigned to Cohorts 1 through 4 may receive up to 3 injections of AA4500 according to cohort assignment. Each injection will be separated by a minimum of 21 days. Subjects assigned to Cohort 5 will receive home shoulder exercises only, while subjects assigned to Cohorts 1-4 will receive AA4500 and home shoulder exercises. Subjects in Cohort 5 will be offered physical therapy sessions for a period of 2 months following completion of the study.
Dosing will range from 0.29 mg to 0.58 mg with varying volumes.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Be a male or female and be greater than or equal to 18 years of age
- •If a female of childbearing potential, have a negative urine pregnancy test and be using an effective contraception method (ie, abstinence, intrauterine device (IUD), hormonal (estrogen/progestin) contraceptives, or barrier control) for at least one menstrual cycle prior to study enrollment and for one menstrual cycle following end of study, or be surgically sterile
- •Have unilateral idiopathic adhesive capsulitis of one shoulder for at least 3 months but not more than 12 months before the screening visit and be in Stage 2 (frozen or adhesive stage), as determined by the investigator
- •Have normal range of motion in the contralateral shoulder, as determined by the investigator
- •Have restricted active range of motion (AROM) in the affected shoulder defined as: a deficit of at least 60 degrees in total AROM in the affected shoulder as compared with the total AROM in the contralateral shoulder and a deficit of at least 30 degrees in AROM in at least one of the following planes as compared with the contralateral shoulder:
- •Forward flexion
- •Abduction
- •External rotation with the elbow up to 90 degrees abduction
- •Internal rotation with the elbow up to 90 degrees abduction
- •Voluntarily sign and date an informed consent agreement approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC). The subject must also sign an authorization form to allow disclosure of his protected health information (PHI). The PHI authorization form and informed consent form may be an integrated form or may be separate forms depending on the institution.
- •Be able to complete and understand the various rating instruments in English.
Exclusion Criteria
- •Is a pregnant or lactating female or female intending to become pregnant during the study
- •Is a male who intends to father a child during the study
- •Has received treatment for adhesive capsulitis or is planning to receive treatment for adhesive capsulitis at any time during the study including but not limited to:
- •physical therapy or acupuncture within 2 weeks before the first injection of AA4500
- •intra-articular or intrabursal injection(s) of lidocaine; suprascapular nerve blocks; corticosteroids; electroanalgesic and/or thermoanalgesic modalities within 1 month before the screening visit
- •intra-articular or intrabursal injection(s) of sodium hyaluronate within 3 months before the screening visit
- •glenohumeral distension arthrography and/or surgical intervention (including shoulder manipulation under anesthesia) at any time
- •Has any of the following conditions, as determined by the investigator:
- •Adhesive capsulitis as a result of traumatic injury
- •Pain in the affected shoulder at rest that is greater than or equal to 4 on the 11-point pain scale
- •Active subacromial impingement in the affected shoulder
- •Calcified tendonitis in the affected shoulder
- •Glenohumeral joint arthritis in the affected shoulder
- •Arthrosis of the affected shoulder
- •Chondrolysis of the affected shoulder
- •Subscapularis tendon rupture of the affected shoulder
- •Other rotator cuff injuries of the affected shoulder
- •Uncontrolled hypertension
- •Uncontrolled diabetes
- •Uncontrolled thyroid disease
- •History of thrombosis or post-thrombosis syndrome
- •Physical impairment that would preclude performing the protocol defined exercises
- •Active infection in area to be treated
- •Clinically significant neurological disease
- •Coagulation disorder, using anticoagulant (except for less than or equal to 150 mg aspirin) within 7 days prior to each injection day
- •Known active hepatitis B or C (history of hepatitis A permitted)
- •Other significant medical condition (eg, morbid obesity, cervical disc disease), which in the investigator's opinion would make the subject unsuitable for enrollment in the study
- •Is unwilling or unable to cooperate with the requirements of the study including completion of all scheduled study visits.
- •Has received oral or intravenous steroids for any reason within 3 weeks before the screening visit
- •Has received an investigational drug or treatment within 30 days before the first dose of study drug.
- •Has a known systemic allergy to collagenase or any other excipient of AA4500 or any other procedural medication.
- •Has, at any time, received collagenase for the treatment of adhesive capsulitis.
- •Is unable to undergo an x-ray or MRI (contraindication) evaluation of the affected shoulder.
- •Is planning to be treated with commercial Xiaflex at any time during the study.
Outcomes
Primary Outcomes
Change From Baseline to Day 92 in Active Forward Flexion
Time Frame: Baseline, Day 92
Active range of motion (AROM) measurement using a goniometer to assess forward flexion in the affected shoulder
Secondary Outcomes
- Change From Baseline to Day 92 in Passive Forward Flexion(Baseline, Day 92)
- Change From Baseline to Day 92 in Active External Rotation(Baseline, Day 92)
- Change From Baseline to Day 92 in Active Internal Rotation(Baseline, Day 92)
- Change From Baseline to Day 92 in Active Abduction(Baseline, Day 92)
- Change From Baseline to Day 92 in Passive Abduction(Baseline, Day 92)
- Change From Baseline to Day 92 in Passive External Rotation(Baseline, Day 92)
- Change From Baseline to Day 92 in Passive Internal Rotation(Baseline, Day 92)
- Change From Baseline to Day 92 in ASES Function Subscale(Baseline, Day 92)
- Change From Baseline to Day 92 in American Shoulder and Elbow Surgeons (ASES) Composite Score(Baseline, Day 92)
- Change From Baseline to Day 92 in ASES Pain Subscale(Baseline, Day 92)
- Subject Satisfaction With Treatment at Day 92(Day 92)
- Investigator Assessment of Improvement With Treatment at Day 92(Day 92)
Investigators
Study Sites (30)
Loading locations...
Similar Trials
Completed
Phase 1
The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)Edematous Fibrosclerotic PanniculopathyCelluliteNCT01518907Endo Pharmaceuticals99
Completed
Phase 2
Clinical Study for the Treatment of Adhesive Capsulitis of the ShoulderAdhesive CapsulitisFrozen ShoulderNCT02006719Endo Pharmaceuticals322
Completed
Phase 2
Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's DiseasePeyronie's DiseaseNCT01430169Endo Pharmaceuticals20
Completed
Phase 2
Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease NodulesDupuytren's DiseaseNCT02193828Endo Pharmaceuticals76
Completed
Phase 4
Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016)Vaccines, CombinedHexavalent VaccineNCT05289271Merck Sharp & Dohme LLC168